

Age differences in treatment response to a collaborative care intervention for anxiety disorders*†

Julie Loebach Wetherell, Andrew J. Petkus, Steven R. Thorp, Murray B. Stein, Denise A. Chavira, Laura Campbell-Sills, Michelle G. Craske, Cathy Sherbourne, Alexander Bystritsky, Greer Sullivan and Peter Roy-Byrne

Background

Some data suggest that older adults with anxiety disorders do not respond as well to treatment as do younger adults.

Aims

We examined age differences in outcomes from the Coordinated Anxiety Learning and Management (CALM) study, an effectiveness trial comparing usual care to a computer-assisted collaborative care intervention for primary care patients with panic disorder, generalised anxiety disorder, post-traumatic stress disorder (PTSD), and/or social anxiety disorder. This is the first study to examine the efficacy of a collaborative care intervention in a sample that included both younger and older adults with anxiety disorders. We hypothesised that older adults would show a poorer response to the intervention than younger adults.

Method

We examined findings for the overall sample, as well as within each diagnostic category (clinicaltrials.gov identifier: NCT00347269).

Results

The CALM intervention was more effective than usual care among younger adults overall and for those with generalised anxiety disorder, panic disorder and social anxiety disorder. Among older adults, the intervention was effective overall and for those with social anxiety disorder and PTSD but not for those with panic disorder or generalised anxiety disorder. The effects of the intervention also appeared to erode by the

18-month follow-up, and there were no significant effects on remission among the older adults.

Conclusions

These results are consistent with the findings of other investigators suggesting that medications and psychotherapy for anxiety disorders may not be as effective for older individuals as they are for younger people.

Declaration of interest

J.L.W. received research support from Forest Laboratories. M.B.S. receives or received research support from the US Department of Defense, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, National Institutes of Health and the US Veterans Affairs Research Program; and is currently or has been a paid consultant for AstraZeneca, Avera Pharmaceuticals, BrainCells, Bristol-Myers Squibb, Comprehensive NeuroScience; Eli Lilly, Forest Laboratories, GlaxoSmithKline, Hoffmann-La Roche, Jazz Pharmaceuticals, Johnson & Johnson, Mindsite, Pfizer, Sepracor, and Transcept Pharmaceuticals. P.R.-B. receives research grant support from the National Institutes of Health; served as a paid member of advisory boards for Jazz Pharmaceuticals and Solvay Pharmaceuticals (one meeting for each); received honoraria for continuing medical education (CME)-sponsored speaking from the American Psychiatric Association, Anxiety Disorders Association of America, CME LLC, CMP Media, Current Medical Directions, Imedex, Massachusetts General Hospital Academy, and PRIMEDIA Healthcare.

In both younger and older adults, anxiety disorders are the most common form of psychiatric illness.1,2 The consequences of anxiety disorders in later life can be severe, including increased risk of cardiovascular disease,3 other serious medical illness4 and cognitive impairment.⁵ Although treatment for anxiety disorders is generally effective, some data suggest that older people respond less well than younger people do. $^{6-12}$ Most studies of anxiety treatment in 'adult' populations have excluded elderly individuals, however, precluding a direct comparison of treatment outcome across age groups within a single trial. In the present investigation, we examine age differences in outcomes from the Coordinated Anxiety Learning and Management (CALM) study (clinicaltrials. gov identifier: NCT00347269), an effectiveness trial comparing usual care to a collaborative care intervention for primary care patients with panic disorder, generalised anxiety disorder, posttraumatic stress disorder (PTSD) or social anxiety disorder.¹³ We hypothesised that older adults would show a poorer response

*A version of this paper was presented at the annual meeting of the Anxiety Disorders Association of America, Washington, DC, 12–15 April 2012.

†See editorial, pp. 8-9, this issue.

to the intervention than younger adults. We examined findings for the overall sample, as well as within each diagnostic group.

Method

Participants

The development and details of the methodology used in the CALM study have been described elsewhere. 14,15 Primary care patients diagnosed with panic disorder, generalised anxiety disorder, PTSD and social anxiety disorder (as single disorders or in combination) were referred by primary care professionals (internists and family physicians) from 17 clinics at four sites in the USA: Little Rock, Arkansas; Los Angeles County and San Diego, California; and Seattle, Washington. The 1004 randomised participants ranged in age from 18 to 75. Clinical inclusion was based on meeting DSM-IV diagnostic criteria, as assessed by trained interviewers who administered the Mini International Neuropsychiatric Interview, 16 and also at least moderate anxiety severity and impairment as assessed by the Overall Anxiety Severity and Impairment Scale. 17 Written informed consent was obtained from all participants after study procedures were explained.

Measures

Outcome assessments were conducted via telephone by raters masked to treatment assignment at baseline, 6 months, 12 months and 18 months. The primary outcome of interest was the Brief Symptom Inventory (BSI) Anxiety subscale. This self-report instrument consists of six Likert-scored items measuring symptoms of worry and autonomic arousal. Internal consistency as measured by Cronbach's alpha at baseline in the present sample was 0.84 for both younger and older adults.

Somatic symptoms were assessed with the BSI Somatic subscale, ¹⁸ which also comprises six Likert-scored items and measures cardiac, gastrointestinal and other bodily sensations. Cronbach's alpha was 0.78 for the younger adults and 0.73 for the older adults. Depressive symptoms were measured with the Patient Health Questionnaire (PHQ). ¹⁹ The nine-item PHQ was administered at baseline; an eight-item version (with the suicide item omitted) was administered at the 6-, 12- and 18-month follow-up periods. Outcome analyses were based on the eight-item score. The Cronbach's alpha of the eight-item PHQ at baseline was 0.85 for both younger and older adults.

Among the subset of participants with generalised anxiety disorder, the Generalized Anxiety Disorder Severity Scale (GADSS)²⁰ was used to assess symptoms. The Cronbach's alpha of the GADSS at baseline was 0.82 among the younger adults and 0.81 among the older adults. The Panic Disorder Severity Scale (PDSS) was administered to patients with panic disorder.²¹ Cronbach's alpha was 0.87 for both younger and older adults. Patients with social phobia completed the Social Phobia Inventory (SPIN).²² Cronbach's alphas were 0.91 for the younger adults and 0.93 for the older adults. Finally, the PTSD Checklist (PCL) measured PTSD symptoms among patients with that diagnosis.²³ Cronbach's alphas in the present sample were 0.88 for the younger adults and 0.89 for the older adults.

Usual care

Patients in the usual care condition received their usual treatment from their physician. At the baseline assessment, 62.1% of the patients in this condition were receiving any psychotropic medication, and 46.7% were receiving counselling. However, only 30.6% of the patients were receiving an adequate dose (i.e. either the maximum dose tolerated or the maximum suggested by the manufacturer) of an appropriate psychotropic medication (usually an selective serotonin reuptake inhibitor (SSRI) or serotonin–noradrenaline reuptake inhibitor (SNRI)) for at least 2 months and only 4.6% were receiving consistent cognitive–behavioural therapy (CBT, i.e. usually or always received three or more essential CBT elements, such as exposure, cognitive restructuring and homework) for their anxiety at baseline.

Collaborative care

The collaborative care intervention was modelled on an intervention that was effective for older primary care patients with major depression. ²⁴ It was managed by anxiety clinical specialists (ACSs). The ACSs were 11 women and 3 men, including 6 social workers, 5 registered nurses and 3 psychologists (2 master's level and 1 doctoral level). All ACSs had experience working with patients in a primary care setting for an average of 12 years. Eight had mental health experience, four with CBT, and seven had experience managing medications.

Patients in the collaborative care condition were able to choose pharmacotherapy, CBT or both. The ACSs managed the pharmacotherapy, which was prescribed by primary care physicians, to patients who preferred it and for whom it was not contraindicated. A manual for CALM pharmacotherapy

included the medication algorithm, strategies for discussing medications with patients, protocols for monitoring medications, managing side-effects and indications for choosing specific medications. The ACS received didactic training and ongoing weekly supervision from a local study psychiatrist in which cases were reviewed and further training was provided on medication management.

The first-line pharmacological treatment for most patients was an SSRI or an SNRI, chosen based on the patient's psychopharmacological history and potential interactions with other medications. For patients who had not responded to SSRI or SNRI medications in the past, a benzodiazepine or GABAergic agent (such as gabapentin or pregabalin) was prescribed initially. Doses of all medications were titrated to the maximal tolerated dose over a period of 4-6 weeks. Each pharmacological treatment was maintained for at least 10-12 weeks; non-responders to first-line SSRIs were switched to another SSRI, an SNRI, a benzodiazepine or a GABAergic, or in some cases to CBT. Treatment for partial responders to first-line SSRI or SNRI pharmacotherapy could be augmented with benzodiazepines, a GABAergic or CBT. Third-line pharmacological strategies included other classes of antidepressants such as mirtazapine or tricyclics, with atypical antipsychotics as a fourth-line option, in all cases with or without CBT.

The ACSs, under weekly supervision from a psychologist, also delivered the CBT intervention, usually in 6-8 weekly sessions. Prior to delivering study treatments, the ACSs received intensive training in CBT, motivational interviewing and outreach strategies. The ACSs delivered treatment following the CALM model, which included a web-based symptom monitoring system and a computer-assisted programme for delivering the CBT. The training included role-playing and successful completion of two to six training cases, which were audiotaped, reviewed by supervisors and rated for adherence and competence. The ACSs were not permitted to see randomised patients until they demonstrated adequate proficiency on at least 50% of their training cases. Although the web-based system allowed supervisors to monitor treatment elements delivered, patient progress and potential problems with the treatment process, adherence and competence were not rated on an ongoing basis.

Statistical analyses

Analyses were conducted by using SAS version 9.1 for Windows 7. Sample characteristics were computed for the older (aged 60–75) and younger adult (aged 18-59) groups. Age differences were examined using chi-squared tests for categorical variables and t-tests for continuous variables. Outcomes were examined both as dichotomous and as continuous variables for the older and younger samples separately, with appropriate covariates included in the models. Logistic regression analyses were used to predict treatment response, as defined by a reduction in BSI Anxiety score of 50% or more relative to baseline, and remission, as defined by BSI Anxiety score less than three. Mixed-model analyses were conducted to examine change in the outcome variables. The restricted maximum likelihood approach was used to fit the models. This approach allows for the use of all available data and accounts for missing data at subsequent time points.^{25,26} Each model included time (baseline, 6 months, 12 months, 18 months), treatment condition (intervention v. usual care), and the time × treatment interaction. Time was treated as a categorical variable. The intercept and time were also included as random effects in the model. The proposed model was fit using a restricted maximum likelihood approach. The estimated means for each treatment group at each time point were generated. In addition to examining the significance of the overall model, we compared the means scores for the intervention and usual care at each time point. We performed analyses with the BSI Anxiety and Somatic subscales and PHQ as dependent variables using the overall sample. We also performed separate analyses for each diagnostic subgroup using the appropriate diagnosis-specific measure (GADSS for those with generalised anxiety disorder; PDSS for those with panic disorder, etc.).

Results

Of the 1004 participants in the CALM study, 134 (13.3%) were 60-75 years of age. Demographic and baseline clinical information for the sample is displayed in Table 1. Not surprisingly, older adults had on average a higher number of chronic medical conditions and more visits to medical specialists than did younger adults, although the groups did not differ significantly on primary care visits. Older adults also had lower levels of education, were more likely to be White, and were less likely to be working. They did not differ from younger adults by gender or marital status. In terms of diagnoses, a significantly lower proportion of older than younger individuals met criteria for social anxiety disorder (26.1% v. 42.3%, $\chi^2 = 12.65$, P < 0.001) and panic disorder (35.8% v. 49.5%, $\chi^2 = 8.76$, P = 0.003); age differences in rates of generalised anxiety disorder (74.6% v. 75.3%, $\chi^2 = 0.27$, P = 0.87), PTSD $(23.1\% \text{ v. } 17.2\%, \chi^2 = 2.73, P = 0.10)$ and major depression $(70.1\% \text{ v. } 63.6\%, \chi^2 = 2.20, P = 0.14)$ were not statistically significant. Scores on symptom scales did not differ by age. Older adults had, on average, fewer anxiety disorders than did younger adults. All analyses controlled for education, number of chronic medical conditions, the presence of more than one anxiety disorder diagnosis and the presence of comorbid major depression.

Statistically equivalent proportions of younger (n = 442, 50.8%) and older adults (n = 61, 45.5%, $\chi^2 = 1.30$, P = 0.26) were randomised to the collaborative care intervention. Among the younger adults, 11.3% (n = 50) in the collaborative care condition and 15.0% (n = 64) in the usual care condition, $\chi^2 = 2.53$, P = 0.12, were missing data at the 6-month assessment period.

Comparable data for the 12- and 18-month periods were 19.2% (n=85) $v.\ 20.8\%$ (n=89), $\chi^2=0.33$, P=0.56, and 19.7% (n=87) $v.\ 22.2\%$ (n=95), $\chi^2=0.83$, P=0.36. Among the older adults, rates of missing data at the 6-, 12- and 18-month assessment for the collaborative care and usual care arms, respectively, were 11.5% (n=7) $v.\ 9.6\%$ (n=7), $\chi^2=0.13$, P=0.73; 13.1% (n=8) $v.\ 12.3\%$ (n=9), $\chi^2=0.02$, P=0.90; and 13.1% (n=8) $v.\ 15.1\%$ (n=11), $\chi^2=0.10$, P=0.75. Across both treatment conditions, a higher proportion of younger adults (20.0%, n=174) than older adults (12.7%, n=17) were missing data at the 12-month assessment period, $\chi^2=4.03$, $\chi^2=0.74$, $\chi^2=0.7$

	Age grou	o, years	Tota	al, <i>n</i>		
	18–59	60–75	18–59	60–75	χ^2 or <i>t</i> -test	Р
Gender, <i>n</i> (%)			870	134	< 0.01	0.9
Male	251 (28.9)	39 (29.1)				
Female	619 (71.1)	95 (70.9)				
Hispanic, n (%)	174 (20.0)	22 (16.4)	870	134	0.95	0.3
Ethnicity, n (%)			870	134		
American Indian	51 (5.8)	7 (5.2)			0.90	0.7
Asian	39 (4.4)	1 (0.7)			4.25	0.0
Pacific Islander	19 (2.2)	1 (0.7)			1.23	0.5
African American	109 (12.5)	7 (5.2)			6.37	0.0
White	482 (55.4)	86 (64.2)			7.65	0.0
Other	105 (12.1)	19 (14.2)			0.14	0.7
Education, n (%)			870	134	7.80	0.0
<12 years	42 (4.8)	13 (9.8)				
12 years	138 (15.9)	27 (20.3) ^a				
> 12 years	689 (79.3) ^a	93 (69.9) ^a				
Married or cohabiting, n (%)	466 (53.6)	73 (54.9) ^a	870	134	0.08	0.7
Employed, n (%)	655 (75.5) ^b	53 (39.6)	870	134	72.20	< 0.0
Major chronic medical conditions, n (s.d.)	2.1 (1.9)	3.7 (2.2)	870	134	-8.26	< 0.0
Primary care visits	4.3 (4.2)	5.0 (5.8)	870	134	— 1.69	0.0
Medical specialist visits	1.0 (2.4)	1.7 (2.8)	870	134	-2.60	0.0
Number of anxiety disorders, n (%)			870	134	11.4	0.0
One	346 (39.8)	73 (54.5)				
Two	345 (39.7)	44 (32.8)				
Three	147 (16.9)	15 (11.2)				
Four	32 (3.7)	2 (1.5)				
Measures, n (s.d.)						
Brief Symptom Inventory Anxiety subscale T-score	65.2 (8.6)	65.7 (8.4)	870	134	-0.66	0.5
Brief Symptom Inventory Somatic subscale T-score	60.4 (9.7)	60.8 (9.1)	870	134	-0.42	0.6
Patient Health Questionnaire	12.7 (6.3)	13.4 (6.5)	870	134	-1.19	0.2
Generalized Anxiety Disorder Severity Scale	13.9 (3.9)	13.9 (3.7)	655	100	-0.06	0.9
Panic Disorder Severity Scale	13.5 (5.8)	13.2 (5.8)	428	47	0.37	0.7
Social Phobia Inventory	38.2 (13.3)	39.7 (14.6)	368	35	-0.62	0.5
PTSD Checklist	55.6 (12.3)	57.5 (13.2)	150	31	-0.78	0.4
a. Missing data for one person. b. Missing data for two people.						

participants who missed the 6- or 12-month assessments did provide data at subsequent assessments.

Among those randomised to collaborative care, 6.6% (n=4) of older adults received medication only, 34.4% (n=21) received CBT only and 59.0% (n=36) received combined treatment. Comparable data for the younger adults were 8.8% (n=39), 32.8% (n=145), and 53.6% (n=237) respectively, with another 21 (4.8%) receiving neither CBT nor medications. Treatment type did not differ by age, $\chi^2(3)=3.55$, P=0.31. Of those receiving CBT, 68.4% (n=39) of older adults and 75.7% (n=289) of younger adults completed at least 6 sessions, $\chi^2=1.37$, P=0.24. Detailed information on medications by age group and treatment condition at each time point is presented in Table 2.

Among younger adults, those receiving the intervention were more likely to respond and remit at all time points than were those who received usual care (Table 3). Among older adults, the intervention was associated with higher response rates at 12 months, but not at 6 or 18 months. The intervention was not associated with significantly higher remission rates than usual care at any time point for the older adults. These analyses were also run with participants with missing data assumed to be non-responders and not remitted; results did not change substantially.

With respect to anxiety symptoms as measured by the BSI Anxiety subscale, the overall treatment \times time interaction was significant among both younger (F(3,862) = 6.39, P = 0.0003)

and older $(F(3,127)=3.21,\ P=0.03)$ participants. Among the younger adults, the CALM intervention was equivalent to usual care at baseline and superior to usual care at all subsequent time points (Fig. 1). Among older adults, the CALM intervention was superior to usual care at 12 months but not at 6 or 18 months. For somatic symptoms, the CALM intervention was superior among the younger adults $(F(3,862)=5.35,\ P=0.001)$ but not among the older adults overall or at any time point $(F(3,127)=0.79,\ P=0.50;\ \text{Fig. 2})$. For depressive symptoms as measured by the PHQ, the treatment × time interaction was significant in the younger $(F(3,862)=8.24,\ P<0.0001)$ and older groups $(F(3,127)=3.36,\ P=0.02)$, with the intervention superior to usual care at all follow-up points among the younger adults and at 12 months among the older individuals (Fig. 3).

Among the patients with generalised anxiety disorder, the intervention was significantly better than usual care for generalised anxiety disorder symptoms as measured by the GADSS in the younger group (F(3,648) = 6.93, P < 0.0001) but not in the older group (F(3,93) = 2.26, P = 0.09; Fig. 4). Similarly, for patients with panic disorder, the intervention was significantly better than usual care for panic symptoms among the younger adults (F(3,420) = 3.84, P = 0.01), but not among the older adults (F(3,41) = 2.06, P = 0.12; Fig. 5). Results favoured the collaborative care intervention relative to usual care for older adults with social phobia (F(3,28) = 5.22, P = 0.006; Fig. 6) and PTSD

and treatment condition a	· · · · · · · · · · · · · · · · · · ·	cations at an appropriate dose for at least 2 months by age
	% (n)	χ ² (P)

	% (n)				χ^2 (P)			
Class of drug, at appropriate dose for 2 months or more	Younger CALM	Younger usual care	Older CALM	Older usual care	Younger CALM v. younger usual care	Older CALM v. older usual care	Younger CALM v. older CALM	Younger usua care v. older usual care
Baseline								
Any appropriate agent	27.7 (120)	29.5 (124)	37.9 (22)	36.6 (26)	0.37 (0.55)	0.23 (0.88)	2.63 (0.11)	1.44 (0.23)
Antidepressant	25.7 (112)	26.3 (111)	27.1 (16)	31.5 (23)	0.04 (0.84)	0.30 (0.58)	0.06 (0.82)	0.85 (0.36)
Benzodiazepine	2.8 (12)	5.4 (23)	10.0 (6)	4.2 (3)	3.88 (0 .05)	1.69 (0.19)	7.83 (<0.01)	0.18 (0.67)
Other anti-anxiety agent	2.0 (9)	0.9 (4)	5.0 (3)	5.5 (4)	0.37 (0.55)	0.02 (0.90)	1.99 (0.16)	8.20 (<0.01
6 months								
Any appropriate agent	46.1 (178)	42.3 (151)	51.0 (26)	37.5 (24)	1.10 (0.30)	2.10 (0.15)	0.43 (0.51)	0.51 (0.47)
Antidepressant	44.3 (172)	37.3 (134)	43.4 (23)	36.9 (24)	3.78 (0.52)	0.51 (0.48)	0.02 (0.90)	0.01 (0.95)
Benzodiazepine	4.4 (17)	8.3 (30)	11.3 (6)	1.5 (1)	4.94 (0.03)	5.01 (0.03)	4.62 (0.04)	3.71 (0.06)
Other anti-anxiety agent	1.8 (7)	0.8 (3)	3.9 (2)	1.5 (1)	1.36 (0.24)	0.62 (0.43)	0.95 (0.33)	0.30 (0.58)
12 months								
Any appropriate agent	41.4 (146)	35.5 (117)	55.1 (27)	38.7 (24)	2.51 (0.12)	2.96 (0.09)	3.31 (0.07)	0.24 (0.62)
Antidepressant	40.4 (143)	31.6 (105)	45.1 (23)	38.7 (24)	5.71 (0.02)	0.47 (0.50)	0.41 (0.52)	0.19 (0.28)
Benzodiazepine	4.3 (15)	6.6 (22)	11.5 (6)	3.1 (2)	1.79 (0.18)	3.16 (0.08)	4.84 (0.03)	1.14 (0.29)
Other anti-anxiety	1.1 (4)	0.9 (3)	3.9 (2)	3.9 (2)	0.10 (0.76)	0.05 (0.83)	2.38 (0.13)	2.23 (0.14)
18 months								
Any appropriate agent	39.6 (140)	36.4 (118)	49.0 (25)	40.0 (24)	0.70 (0.40)	0.91 (0.34)	1.66 (0.20)	0.28 (0.60)
Antidepressant	38.1 (135)	32.8 (107)	39.2 (20)	40.0 (24)	2.09 (0.15)	0.01 (0.93)	0.02 (0.88)	1.16 (0.28)
Benzodiazepine	4.8 (17)	5.7 (19)	9.6 (5)	3.2 (2)	0.29 (0.59)	2.00 (0.16)	2.03 (0.15)	0.65 (0.42)
Other anti-anxiety	1.4 (5)	1.2 (4)	3.9 (2)	3.2 (2)	0.05 (0.82)	0.03 (0.86)	1.59 (0.21)	1.41 (0.24)

a. Results in bold are statistically significant.

Table 3 Adjusted odds ratios associated with response and remission to a collaborative care intervention for anxiety disorders relative to usual care by age group^a

	Response (BSI	Anxiety decrease ≥50	%), OR (95% CI)	Remission (BSI Anxiety score <3), OR (95% CI)						
	6 months	12 months	18 months	6 months	12 months	18 months				
Younger	2.15 (1.60-2.89)	2.24 (1.64-3.04)	1.83 (1.34-2.49)	2.37 (1.69-3.33)	1.86 (1.35-2.56)	2.16 (1.56-2.98)				
Older	1.47 (0.69–3.12)	4.04 (1.81–9.00)	1.70 (0.79–3.65)	1.94 (0.78–4.80)	1.75 (0.80–3.83)	1.08 (0.49–2.38)				

BSI, Brief Symptom Inventory.

a. Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and major depression at baseline. Results in bold are statistically significant.




Fig. 1 Anxiety symptoms in (a) younger (n= 870) and (b) older (n= 134) primary care patients with anxiety disorders receiving a collaborative care intervention (TX) or usual care (TAU).

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. BSI, Brief Symptom Inventory.




Fig. 2 Somatic symptoms in (a) younger (n = 870) and (b) older (n = 134) primary care patients with anxiety disorders receiving a collaborative care intervention (TX) or usual care (TAU).

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. BSI, Brief Symptom Inventorv.




Fig. 3 Depressive symptoms in (a) younger (n=870) and (b) older (n=134) primary care patients with anxiety disorders receiving a collaborative care intervention (TX) or usual care (TAU).

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. PHQ, Patient Health Questionnaire

(F(3,25) = 3.02, P < 0.05; Fig. 7); results for younger adults favoured the collaborative care intervention for those with social phobia (F(3,363) = 8.81, P < 0.0001) but not for those with PTSD (F(3,143) = 2.15, P = 0.10).

Discussion

Main findings

The CALM collaborative care intervention was more effective than usual care in younger adults overall and among those with generalised anxiety disorder, panic disorder and social phobia, although not among those with PTSD. This was true for almost all measures at all follow-up time points, in terms of symptom levels and responder and remitter status. In older adults, however, the intervention was only significantly better on anxiety and depressive symptoms than usual care at 12 months, effects appeared to erode by the 18-month follow-up, and there were no significant effects on remission at any time point. Effects were not significant for somatic symptoms in older adults, but the somatic subscale may have reflected medical illness rather than emotional distress. Among patients with generalised anxiety disorder and panic disorder, the collaborative care intervention was not more effective than usual care among the older adults at any time point, but results in the older panic disorder subsample may have been influenced by the low sample size. Overall, these findings are consistent with those of other investigators suggesting that medications 10,11 and CBT for anxiety disorders 8,9,12 may not be as effective for older individuals as they are for younger people.

Although neither the type of care received nor the attrition rates differed between older and younger adults, older adults took longer to respond to the collaborative care intervention than did




Fig. 4 Generalised anxiety disorder symptoms in (a) younger (n=655) and (b) older (n=100) primary care patients with generalised anxiety disorder receiving a collaborative care intervention (TX) or usual care (TAU).

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. GADSS, Generalized Anxiety Disorder Severity Scale.




Fig. 5 Panic disorder symptoms in (a) younger (n= 428) and (b) older (n= 47) primary care patients with panic disorder receiving a collaborative care intervention (TX) or usual care (TAU).

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. PDSS, Panic Disorder Severity Scale.




Fig. 6 Social phobia symptoms in (a) younger (n= 368) and (b) older (n= 35) primary care patients with panic disorder receiving a collaborative care intervention (TX) or usual care (TAU).

12 months

18 months

6 months

Baseline

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. SPIN, Social Phobia Inventory.




Fig. 7 Post-traumatic stress disorder (PTSD) symptoms in (a) younger (n=150) and (b) older (n=31) primary care patients with panic disorder receiving a collaborative care intervention (TX) or usual care (TAU).

Controlled for education, number of chronic medical conditions, presence of more than one anxiety disorder and comorbid major depression. PCL, PTSD Checklist.

younger adults, and they were more likely to experience a recurrence of symptoms at 18-month follow-up. Age-related pharmacodynamic and learning factors may be responsible for the delayed and less robust treatment response among older adults.

Because pharmacological^{27,28} and behavioural^{29,30} treatments are effective for depression in older adults, it is unlikely that factors directly related to ageing such as medical illness, medication use or cognitive impairment are completely responsible for the decreased efficacy of treatment for anxiety in older adults. It is plausible that the chronic nature of anxiety disorders may account for their resistance to treatment in later life. Generalised anxiety disorder in particular is a highly chronic condition, which in older adults has an average duration of 20 years or more before presentation for treatment.^{31,32} By contrast, depression in older adults is both more episodic and more likely to develop for the first time in old age.^{2,33} Unfortunately, age at onset data were not collected in the present study to allow us to test for the effects of duration in this sample.

It is possible that some features of the collaborative care intervention are responsible for its relative lack of effectiveness among older adults. For example, it was delivered by primary care healthcare workers, many of whom had limited experience delivering mental health services before the trial, the CBT was limited to 6–8 sessions, and it was not modified for older individuals. It may be that older adults with anxiety disorders, unlike those with major depression, require specialty care from seasoned mental health professionals, modified CBT and/or a longer course of treatment. These are empirical questions that should be addressed in future research.

It is also possible that characteristics of the older adults enrolled in this trial influenced the results. Older individuals with anxiety disorders presenting in primary care may differ in important ways from anxious older adults presenting to mental health clinics or those participating in clinical trials of anxiety treatments. Moreover, because cognitive performance was not assessed, some participants in the present study may have had cognitive impairment that affected their response to the intervention.

This study represents, to our knowledge, the first investigation to examine the efficacy of a collaborative care intervention in a sample that included both younger and older adults with anxiety disorders. As such, it represents a methodological advance over meta-analyses that attempt to compare effect sizes across studies. The CALM study was a large-scale, well-designed, and carefully conducted investigation. Moreover, the setting was in primary care, where most older (and younger) adults with anxiety disorders present for treatment, 34–36 suggesting that the findings are likely generalisable to the broader population of individuals seeking help for anxiety.

Collaborative care models are more common in other high-income nations than in the USA, where the reimbursement system poses obstacles to the practice of non-mental health providers performing mental health interventions. Therefore, it is possible that anxious older adults would fare better in countries with well-established collaborative care networks employing highly experienced care management specialists. Collaborative care for depression in older adults does appear to work in the USA, however, 24 suggesting that the nationality of the current trial cannot completely explain the results.

Limitations

The present study has several limitations. First, this is a secondary analysis of data from an effectiveness study of a collaborative care intervention in primary care. Because it was a secondary analysis, participants were not randomised stratified by age, although no significant differences were found in the proportion of younger

and older adults randomised to the intervention. Effectiveness studies differ from efficacy studies in that they attempt to assess how well a treatment works in real-world settings, as opposed to a tightly controlled research setting in which, for example, therapy sessions are videotaped and rated for adherence and competence throughout the duration of the trial and blood samples are drawn to measure adherence to pharmacotherapy. It is not uncommon for treatments that work in efficacy trials to fail when exported outside of the laboratory. This may explain the fact that although prior studies have shown CBT and pharmacotherapy to be efficacious relative to pill placebo, waiting list or usual care for generalised anxiety disorder and panic disorder in older adults, 37-39 such was not the case here. Additionally, studies of collaborative care interventions are intended to answer questions about care delivery models rather than specific treatments. As such, important issues such as the comparative efficacy of various types of treatments and the appropriate dose (including the optimal number of CBT sessions) are not addressed. Future research should investigate age differences in response to medications, psychotherapy and their combination for anxiety disorders in a more tightly controlled efficacy trial.

Although the CALM study is the third largest investigation of anxiety treatment in older adults ever conducted, the number of elderly individuals was still relatively small. A fourfold increase in the sample size needed for adequate power to detect a significant two-way interaction is required to detect a significant three-way interaction (i.e. including age as a factor along with time and treatment condition), 40 which is why we modelled data from younger and older participants separately. People older than 75 were excluded from participation; if ageing does diminish the effects of anxiety treatment, the exclusion of the very old may have biased the results away from a finding of significant age differences. Finally, the comparison condition consisted of treatment as usual in the primary care setting, rather than a consistent alternative treatment or active control condition.

Implications

The most positive message from this study is that people as old as 75 with anxiety disorders do appear to benefit from a collaborative care intervention, relative to usual care, albeit not as much as younger adults do. Another clinical implication of these findings is that older adults with generalised anxiety disorder or panic disorder may require closer monitoring and more intensive treatment than do younger people with these disorders or than older adults with other anxiety disorders. Additionally, older people with anxiety disorders may benefit from periodic booster sessions to ensure that treatment gains are maintained.

Julie Loebach Wetherell, PhD, Psychology Service, VA San Diego Healthcare System, San Diego, and Department of Psychiatry, University of California, San Diego, California; Apetkus, MA, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, California; Steven R. Thorp, PhD, Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, and University of California, San Diego, California; Murray B. Stein, MD, MPH, Department of Psychiatry, University of California; San Diego, California; PhD, Department of Psychiatry, University of California, San Diego, and Department of Psychology, California State University, San Marcos, California; Laura Campbell-Sills, PhD, Department of Psychiatry, University of California, San Diego, California, Los Angeles, California; Cathy Sherbourne, PhD, Rand Corporation, Santa Monica, California; Alexander Bystritsky, MD, Department of Psychology, University of California, Los Angeles, California, California, Greer Sullivan, MD, Department of Psychiatry, University of Arkansas, Little Rock, Arkansas, Peter Roy-Byrne, MD, MPH, Department of Psychiatry, University of Washington, Seattle, Washington, USA

Correspondence: Julie Wetherell, PhD, UCSD Department of Psychiatry, 9500 Gilman Drive, Dept. 9111N-1, La Jolla, CA 92093-9111, USA. Email: iwetherell@ucsd.edu

First received 28 Jul 2012, final revision 24 Nov 2012, accepted 30 Jan 2013

Funding

This work was supported by grants U01 MH057858 and K24 MH065324 (P.R.-B.), U01 MH058915 (M.G.C.), U01 MH070022 (G.S.), U01 MH070018 (C.S.) and U01MH057835 and K24 MH64122 (M.B.S.) from the National Institute of Mental Health.

References

- 1 Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML. High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry 2010; 67: 489–96.
- 2 Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.
- 3 Roest AM, Martens EJ, de Jong P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol 2010; 56: 38–46.
- 4 El-Gabalawy R, Mackenzie CS, Shooshtari S, Sareen J. Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. *Gen Hosp Psychiatry* 2011; 33: 556–64.
- 5 Beaudreau SA, O'Hara R. Late-life anxiety and cognitive impairment: a review. *Am J Geriatr Psychiatry* 2008; **16**: 790–803.
- 6 Hendriks GJ, Oude Voshaar RC, Keijsers GP, Hoogduin CA, van Balkom AJ. Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 2008; 117: 403–11.
- 7 Pinquart M, Duberstein PR. Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry 2007; 15: 639–51.
- 8 Gonçalves DC, Byrne GJ. Interventions for generalized anxiety disorder in older adults: systematic review and meta-analysis. J Anxiety Disord 2012; 26: 1–11.
- 9 Gould RL, Coulson MC, Howard RJ. Efficacy of cognitive behavioral therapy for anxiety disorders in older people: a meta-analysis and meta-regression of randomized controlled trials. J Am Geriatr. Soc. 2012; 60: 218–29.
- 10 Préville M, Vasiliadis HM, Bossé C, Dionne PA, Voyer P, Brassard J. Pattern of psychotropic drug use among older adults having a depression or an anxiety disorder: results from the longitudinal ESA study. Can J Psychiatry 2011; 56: 249 57.
- 11 Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72: 1660–8.
- 12 Covin R, Ouimet AJ, Seeds PM, Dozois DJA. A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord 2008; 22: 108–16.
- 13 Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA 2010; 303: 1921–8
- 14 Roy-Byrne P, Veitengruber JP, Bystritsky A, Edlund MJ, Sullivan G, Craske MG, et al. Brief intervention for anxiety in primary care patients. J Am Board Fam Med 2009: 22: 175–86.
- 15 Sullivan G, Craske MG, Sherbourne C, Edlund MJ, Rose RD, Golinelli D, et al. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders. *Gen Hosp Psychiatry* 2007: 29: 379–87.
- 16 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22–33.
- 17 Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, Chavira DA, et al. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord 2009; 112: 92–101.
- 18 Derogatis LR. BSI: Brief Symptom Inventory: Administration, Scoring, and Procedures Manual. NCS Pearson, 1993.

- 19 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16: 606–13.
- 20 Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL. Generalized Anxiety Disorder Severity Scale (GADSS): a preliminary validation study. *Depress Anxiety* 2006; 23: 77–82.
- 21 Houck PR, Spiegel DA, Shear MK, Rucci P. Reliability of the self report version of the Panic Disorder Severity Scale. Depress Anxiety 2002; 15: 183–5.
- 22 Connor KM, Davidson JRT, Churchill LE, Sherwood A, Weisler RH, Foa E. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry 2000; 176: 379–86.
- 23 Weathers FW, Litz BT, Huska JA, Keane TM. The PTSD Checklist Civilian Version. National Center for PTSD. 1994.
- 24 Unützer J, Katon W, Callahan CM, Williams Jr JW, Hunkeler E, Harpole L, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA 2002; 288: 2836–45.
- 25 Little R, Rubin D. Statistical Analysis with Missing Data. John Wiley & Sons, 1987.
- 26 Brick JM, Kalton G. Handling missing data in survey research. Stat Methods Med Res 1996; 5: 215–38.
- 27 Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord 2012; 141: 103–15.
- 28 Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 2006; 163: 1493–501.
- 29 Areán PA, Raue P, Mackin RS, Kanellopoulos D, McCulloch C, Alexopoulos GS. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. Am J Psychiatry 2010; 167: 1391–8.
- 30 Serfaty MA, Haworth D, Blanchard M, Buszewicz M, Murad S, King M. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial. Arch Gen Psychiatry 2009; 66: 1332–340.
- 31 Chou KL. Age at onset of generalized anxiety disorder in older adults. Am J Geriatr Psychiatry 2009; 17: 455–64.
- 32 Gonçalves DC, Byrne GJ. Sooner or later: age at onset of generalized anxiety disorder in older adults. *Depress Anxiety* 2012; 29: 39–46.
- 33 Penninx BW, Nolen WA, Lamers F, Zitman FG, Smit JH, Spinhoven P, et al. Two-year course of depressive and anxiety disorders: results from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord 2011; 133: 76–85
- 34 Klapow J, Kroenke K, Horton T, Schmidt S, Spitzer R, Williams JB. Psychological disorders and distress in older primary care patients: a comparison of older and younger samples. *Psychosom Med* 2002; 64: 635–43.
- 35 Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146: 317–25.
- 36 Rollman BL, Belnap BH, Mazumdar S, Houck PR, Zhu F, Gardner W, et al. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch Gen Psychiatry 2005; 62: 1332–41.
- 37 Lenze EJ, Rollman BL, Shear MK, Dew MA, Pollock BG, Ciliberti C, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA 2009; 301: 295–303.
- 38 Stanley MA, Wilson NL, Novy DM, Rhoades HM, Wagener PD, Greisinger AJ, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA 2009; 301: 1460–7.
- 39 Hendriks GJ, Keijsers GP, Kampman M, Oude Voshaar RC, Verbraak MJ, Broekman TG, et al. A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. Acta Psychiatr Scand 2010; 122: 11–9.
- 40 Heo M, Leon AC. Sample sizes required to detect two-way and three-way interactions involving slope differences in mixed-effects linear models. J Biopharmaceutical Stats 2010; 20: 787–802.